Phase I clinical trials for development of neurotherapeutics task order no. 2 - petrukin
Ended Awarded Last action
- Contract number
- 75N95018F00002
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,737,263
Award facts
- Opportunity
-
- NIHNINDS1501 Solicitation number
- Phase I Clinical Trials for Development of Neurotherapeutics Award Notice · Posted Jun 18, 2015
- Contract value 100% obligated
- $1,737,262.53 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$33,049 | |
| Funding Only Action | -$101,872 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $75,339 | |
| Exercise an Option | $1,638,601 | |
| Funding Only Action | $118,107 | |
| Original award | $40,137 |
About this award
This is a $1,737,262.53 task order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke to PPD Development LP, a global contract research organization (CRO). The task order is for Phase I clinical trials in the development of neurotherapeutics and is part of the larger "Phase I Clinical Trials for Development of Neurotherapeutics" indefinite delivery/indefinite quantity (ID/IQ) contract. The task order has a performance period ending on August 30, 2020 and does not have a set-aside designation. PPD Development has a strong track record of federal contract awards and subcontracts, with over $500 million in prime contracts and $100 million in subcontracted work, primarily supporting clinical trials and research for agencies like HHS, DoD, and various NIH institutes.
Quick answers
Who was awarded contract 75N95018F00002?
75N95018F00002 was awarded to PPD Development LP by National Institute on Drug Abuse (National Institutes of Health) on June 1, 2018.
How much is contract 75N95018F00002 worth?
The government has obligated $1,737,263 on 75N95018F00002.
Which agency awarded contract 75N95018F00002?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95018F00002, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95018F00002 an order under another contract?
Yes. 75N95018F00002 is a delivery order under HHSN271201600005I, an indefinite delivery contract, on Phase I Clinical Trials for Development of Neurotherapeutics.
Was contract 75N95018F00002 competed?
The extent of competition for 75N95018F00002 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award